The Canadian medical biotechnology company said that it has made use of its Rapid Vertical Flow technology to develop its first rapid antigen test
MedMira said that its VYRA COVID-19 Antigen Test has secured the CE mark and the rapid antigen test is now available in Europe and any other countries that accept the certification mark.
The Canadian medical biotechnology company said that it has leveraged its Rapid Vertical Flow (RVF) technology to develop its first rapid antigen test. VYRA COVID-19 Antigen Test is designed for identifying SARS-CoV-2 virus in the swab samples.
According to MedMira, the design of VYRA COVID-19 nasal swab based test is to make it non-invasive and user-friendly in order to make it more appropriate for any settings.
MedMira CEO Hermes Chan said: “Whereas VYRA COVID-19 provides a high-quality single antigen test for the detection of SARS-CoV-2 designed for customers who are worried about a COVID-19 infection, our up-coming VYRA CoV2Flu Antigen Test will further complement our product offering to customers who wish to have a result for COVID-19 or Flu A or Flu B immediately.
“With the increasing infection rates during the next few months and the need for quality rapid testing solutions, MedMira’s VYRA COVID-19 is the fastest and most reliable answer.”
Earlier this year, MedMira received the CE mark approval for its REVEALCovid-19 PLUS total antibody test. REVEALCovid-19 PLUS is intended to detect the presence of total antibodies against SARS-CoV-2 produced by a previous infection or vaccination.
MedMira, which develops and manufactures Rapid Vertical Flow diagnostics, sells its tests globally under the REVEAL, Multiplo, REVEALCOVID-19, and Miriad brands.